Analysts expect Johnson & Johnson (NYSE:JNJ) to report $20.40 billion in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Johnson & Johnson’s earnings, with the highest sales estimate coming in at $20.53 billion and the lowest estimate coming in at $20.28 billion. Johnson & Johnson reported sales of $20.73 billion during the same quarter last year, which indicates a negative year-over-year growth rate of 1.6%. The business is expected to announce its next quarterly earnings results before the market opens on Tuesday, October 13th.
According to Zacks, analysts expect that Johnson & Johnson will report full year sales of $80.86 billion for the current year, with estimates ranging from $80.43 billion to $81.26 billion. For the next financial year, analysts expect that the business will report sales of $87.73 billion, with estimates ranging from $86.42 billion to $88.93 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The business had revenue of $18.34 billion during the quarter, compared to analysts’ expectations of $17.73 billion. During the same quarter last year, the company earned $2.58 earnings per share. The firm’s revenue was down 10.8% on a year-over-year basis.
Several research firms recently weighed in on JNJ. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, September 4th. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price target for the company. in a research note on Tuesday, July 7th. SVB Leerink restated an “outperform” rating on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the stock from $161.00 to $164.00 in a research note on Monday, July 20th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $168.00 price target on shares of Johnson & Johnson in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $163.00.
In related news, EVP Ashley Mcevoy sold 29,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the sale, the executive vice president now owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.
Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. grew its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock worth $27,242,005,000 after acquiring an additional 1,168,129 shares during the period. Geode Capital Management LLC grew its holdings in Johnson & Johnson by 1.5% during the 1st quarter. Geode Capital Management LLC now owns 38,965,156 shares of the company’s stock worth $5,100,421,000 after acquiring an additional 572,077 shares during the period. Wellington Management Group LLP grew its holdings in Johnson & Johnson by 10.8% during the 1st quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock worth $4,006,895,000 after acquiring an additional 2,968,879 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Johnson & Johnson by 7.7% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock worth $3,871,753,000 after acquiring an additional 2,118,870 shares during the period. Finally, Capital World Investors grew its holdings in Johnson & Johnson by 182.9% during the 1st quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock worth $2,779,435,000 after acquiring an additional 13,703,905 shares during the period. 67.44% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE JNJ traded down $1.08 during mid-day trading on Wednesday, hitting $146.24. The company had a trading volume of 5,485,602 shares, compared to its average volume of 8,360,347. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. The business’s 50-day simple moving average is $149.19 and its 200-day simple moving average is $144.96. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The firm has a market cap of $385.02 billion, a P/E ratio of 21.38, a PEG ratio of 3.29 and a beta of 0.68.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.76%. The ex-dividend date of this dividend was Monday, August 24th. Johnson & Johnson’s payout ratio is 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.